MetaTech (AP) Inc. announced that MetroHarbor Hospital to receive approval for the cell preparation site (autologous fibroblast) from the MOHW. Cause of occurrence: According to the Regulations for the Implementation or Use Management of Specific Medical Technologies, Inspections, and Examinations of Medical Devices (hereinafter referred to as Regulations for Special Medical Techniques) by the Ministry of Health and Welfare (hereinafter referred to as the MOHW), company's Cell Processing Center (CPC) operates as a cell preparation site for Tungs' Taichung MetroHarbor Hospital. The application pertains to the cell therapy technology implementation plan for autologous fibroblast transplantation treatment for 'Skin Defects: Filling and Repair of Wrinkles, Depressions, and Scars.

' The designated cell preparation site of METATECH (AP) INC. - CPC was approved by the MOHW on April 2, 2024, in compliance with Good Tissue Practice (GTP) operations; Countermeasures: According to the MOHW's approval letter, if there are any subsequent matters related to the release of significant information, company will be handled in accordance with the regulations; MetroHarbor Hospital application are as follows: (1) Cellular therapy technology: Autologous fibroblast cell therapy, (2) Indications: Filling and repair of skin defects, including wrinkles, depressions, and scars, (3) Cell preparation site: METATECH (AP) INC. - Cell Processing Center (4) Approved validity period: From April 2, 2024 to December 17, 2025.